MedTrace Logo

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

NCT04230954 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-06-07

No results posted yet for this study

Summary

Drug: Cabozantinib Drug: Pembrolizumab

Conditions

  • Cervical Cancer
  • Recurrent Cervical Cancer
  • Metastatic Cervical Cancer
  • Persistent Cervical Cancer

Interventions

DRUG

Cabozantinib 40 MG oral once a day

Cabozantinib 40 mg oral once a day

DRUG

Pembrolizumab 200 mg IV every 3 weeks

Pembrolizumab 200 mg IV every 3 weeks

Sponsors & Collaborators

  • Exelixis

    collaborator INDUSTRY

  • University of South Alabama

    lead OTHER

Principal Investigators

  • Stefanie White · University of South Alabama

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2022-02-16
Completion
2022-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04230954 on ClinicalTrials.gov